000			02053 a2200613 4500
005			20250516082153.0
264		0	_c20120312
008			201203s 0 0 eng d
022			_a1538-3598
024	7		_a10.1001/jama.2012.250 _2doi
040			_aNLM _beng _cNLM
100	1		_aDupuis-Girod, Sophie
245	0	0	_aBevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. _h[electronic resource]
260			_bJAMA _cMar 2012
300			_a948-55 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAngiogenesis Inhibitors _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized _xtherapeutic use
650	0	4	_aArteriovenous Malformations _xetiology
650	0	4	_aBevacizumab
650	0	4	_aCardiac Output _xdrug effects
650	0	4	_aEpistaxis _xetiology
650	0	4	_aFemale
650	0	4	_aHeart Failure
650	0	4	_aHumans
650	0	4	_aLiver _xblood supply
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProspective Studies
650	0	4	_aTelangiectasia, Hereditary Hemorrhagic _xcomplications
650	0	4	_aTreatment Outcome
700	1		_aGinon, Isabelle
700	1		_aSaurin, Jean-Christophe
700	1		_aMarion, Denis
700	1		_aGuillot, Elsa
700	1		_aDecullier, Evelyne
700	1		_aRoux, Adeline
700	1		_aCarette, Marie-France
700	1		_aGilbert-Dussardier, Brigitte
700	1		_aHatron, Pierre-Yves
700	1		_aLacombe, Pascal
700	1		_aLorcerie, Bernard
700	1		_aRivière, Sophie
700	1		_aCorre, Romain
700	1		_aGiraud, Sophie
700	1		_aBailly, Sabine
700	1		_aPaintaud, Gilles
700	1		_aTernant, David
700	1		_aValette, Pierre-Jean
700	1		_aPlauchu, Henri
700	1		_aFaure, Frédéric
773	0		_tJAMA _gvol. 307 _gno. 9 _gp. 948-55
856	4	0	_uhttps://doi.org/10.1001/jama.2012.250 _zAvailable from publisher's website
999			_c21602300 _d21602300